Dr Michelle Tempest and Dr Karen Sayal reveal in this July 2019 #LaingBuisson article promising opportunities investing in #immunotherapy treatments
Cancer therapeutic landscape is shifting to more distinct and personalised immunotherapy treatments.
With a market expected to almost triple by 2025, several biotech firms are in early #clinicaltrials.
Opportunities arise in
- novel combinations of check-point inhibitors: engineered proteins that bind to cancer cells and indirectly signal an ‘auto-destruct’ response from the immune system
- cellular based immunotherapy that involves, for part, re-infusing specific expanded immune cells (ACT, adoptive cell transfer)
Challenges remain because of the toxicity risk and the high costs associated.
© Candesic 2021